Literature DB >> 26427143

Circulating Double-Stranded DNA in Plasma of Hemodialysis Patients and its Association with Iron Stores.

Luiz Carlos Cichota, Guilherme Vargas Bochi, Etiane Tatsch, Vanessa Dorneles Torbitz, Paula Roberto Dall Agnol, Jean Carlos Zanardo, Fernanda Barbisan, Ivana Beatrice Mânica da Cruz, Rodrigo de Almeida Vaucher, Rafael Noal Moresco.   

Abstract

BACKGROUND: Chronic kidney disease (CKD) is characterized by oxidative stress, and most of the adverse effects of CKD are mediated by iron-catalyzed ROS generation. The DNA, in particular, is more susceptible to attack by ROS than other proteins and membrane lipids. Considering the evidence on the relationship between CKD, iron metabolism, and DNA damage, the purpose of this study was to evaluate cell-free DNA in the plasma of HD patients and its association with iron status biomarkers and kidney function.
METHODS: Measurements of the circulating cell-free DNA in plasma, iron, ferritin, transferrin and other biochemical parameters were performed in 40 chronic hemodialysis (HD) patients and 40 healthy controls. Blood samples were also collected 1 hour before and 1 hour after the HD session to check whether a single HD session would be able to promote an increase in cell-free DNA in the plasma.
RESULTS: Cell-free DNA in plasma was significantly increased in HD patients in comparison with healthy controls (p = 0.0017), and significant correlations were observed between cell-free DNA and GFR and ferritin. Our findings showed that a single HD session was not able to promote an increase in cell-free DNA. It was reported that increased ferritin levels and reduced GFR were associated with higher circulating cell-free DNA.
CONCLUSIONS: The HD patients presented increased ceIl-free DNA. In addition, the increase of ferritin levels and the decrease of GFR were associated with DNA damage. We also observed that a single HD session was not able to promote an increase in cell-free DNA.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26427143     DOI: 10.7754/clin.lab.2015.141239

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  6 in total

1.  Prognostic utility of admission cell-free DNA levels in patients with chronic obstructive pulmonary disease exacerbations.

Authors:  Avital Avriel; Dmitry Rozenberg; Yael Raviv; Dov Heimer; Amir Bar-Shai; Rachel Gavish; Jony Sheynin; Amos Douvdevani
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-12-09

Review 2.  Measurement of iron status in chronic kidney disease.

Authors:  Wesley Hayes
Journal:  Pediatr Nephrol       Date:  2018-04-17       Impact factor: 3.714

Review 3.  DNA Damage in Chronic Kidney Disease: Evaluation of Clinical Biomarkers.

Authors:  Nicole Schupp; Helga Stopper; August Heidland
Journal:  Oxid Med Cell Longev       Date:  2016-05-25       Impact factor: 6.543

4.  Diagnostic utility of a Ferritin-to-Procalcitonin Ratio to differentiate patients with COVID-19 from those with Bacterial Pneumonia: A multicenter study.

Authors:  Amal A Gharamti; Fei Mei; Katherine C Jankousky; Jin Huang; Peter Hyson; Daniel B Chastain; Jiawei Fan; Sharmon Osae; Wayne W Zhang; José G Montoya; Kristine M Erlandson; Sias J Scherger; Carlos Franco-Paredes; Andrés F Henao-Martínez; Leland Shapiro
Journal:  medRxiv       Date:  2020-10-22

Review 5.  The Other Obesity Epidemic-Of Drugs and Bugs.

Authors:  Adonis Sfera; Carolina Osorio; Eddie Lee Diaz; Gerald Maguire; Michael Cummings
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-31       Impact factor: 5.555

6.  Diagnostic Utility of a Ferritin-to-Procalcitonin Ratio to Differentiate Patients With COVID-19 From Those With Bacterial Pneumonia: A Multicenter Study.

Authors:  Amal A Gharamti; Fei Mei; Katherine C Jankousky; Jin Huang; Peter Hyson; Daniel B Chastain; Jiawei Fan; Sharmon Osae; Wayne W Zhang; José G Montoya; Kristine M Erlandson; Sias J Scherger; Carlos Franco-Paredes; Andrés F Henao-Martínez; Leland Shapiro
Journal:  Open Forum Infect Dis       Date:  2021-03-14       Impact factor: 3.835

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.